Published in Blood Weekly, November 18th, 2004
The company said that the gross margin earned on product sales exceeded 50% for the second quarter in a row. Despite increasing its investment in research and clinical trial support for StaphVAX (Staphylococcus aureus Polysaccharide Conjugate Vaccine) by $12.3 million from 2003 levels, operating cash flow totaled a positive $5.2 million in the 2004 third quarter. Led by increases in year-to-date biopharmaceutical sales, including the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.